GlassScriptPhysician profile
Kristin Wickham
NPI 1013368968
$5,944.39
in general payments reported to CMS, 2019-2025
36 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $425 · 2021: $729 · 2022: $668 · 2023: $1,109 · 2024: $1,542 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,330.19 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $783.30 | 2020-2025 | |
| Novo Nordisk INC | $692.13 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $511.86 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $289.18 | 2020-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $238.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $230.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $199.22 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.48 | 2020-2024 | Jardiance |
| Glaxosmithkline, LLC. | $167.42 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $161.31 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.00 | 2020-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $129.13 | 2023-2025 | Auvelity, Symbravo |
| Phathom Pharmaceuticals, INC. | $126.55 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $83.31 | 2020-2023 | Eliquis |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Wickham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.